Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9

Benzinga Newsdesk www.benzinga.com Negative 86.4%

Neg 86.4% Neu 0% Pos 0%

Roth Capital analyst Boobalan Pachaiyappan reiterates Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $10 to $9.